Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2002

View Archived Issues

Robust thermogenic responses elicited by new beta3-adrenoceptor agonists identified at GSK

Imunovir distribution agreement for North America extended

Curis reports evidence for a unique mechanism for the renal effects of BMP-7

Potent hypoglycemic and hypolipidemic agent interacting with PPARgamma identified at Takeda

Company Profile: Basilea Pharmaceutica

Bio-Technology General initiates phase I study of Puricase in gout

Pharmacia licenses Nastech's nasally administered apomorphine for ED & FSD

Prana awarded grant for research into age-related diseases

Once-daily one-tablet formulation of Sustiva approved

Fast track designation for Oncophage in metastatic melanoma

Transglutaminase inhibitor improves survival and symptoms in transgenic Huntington's disease mice

EMEA accepts vardenafil submission for treatment of ED

Initiation of phase I clinical trial of XR-11576 in treatment of solid tumors

Medtronic's Activa Parkinson's Control Therapy receives FDA approval

Efalizumab to be evaluated in rheumatoid arthritis

New Janssen compounds with fundic relaxant activity

Polymer-based analgesic successfully completes first clinical trial at A.P. Pharma

AstraZeneca claims compounds which modulate chemokine receptors

AtheroGenics identifies inhibitors of VCAM-1 expression

Servier scientists prepare novel podophyllotoxin derivatives for cancer Rx

Potent and selective PDE7 inhibitors discovered at Celltech

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...